Reply to: Tofacitinib for the Treatment of Severe Alopecia Areata and Variants

In a letter to the editor, Runcie and Kravvas acknowledged the work of Liu et al. on the use of tofacitinib for treating severe alopecia areata but raised concerns about the study's methodology. They found the statistical analysis complex and suggested a simpler graphical representation of patient data before and after treatment. They questioned the categorization of treatment response into broad, arbitrarily defined groups rather than quartiles and challenged the dismissal of steroids as a potential contributing factor to hair regrowth, citing literature that showed steroids could stimulate hair growth. They concluded that more extensive randomized controlled trials are necessary to clarify the role of biologics like tofacitinib in treating alopecia areata.